Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Daniel F. Hoft et al.|The Lancet|2017Cited by 196
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Rafael De La Barrera et al.|The Journal of Infectious Diseases|2020Cited by 24
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, O.S. Adedeji et al.|The Lancet Infectious Diseases|2023Cited by 23
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Emmanuel Feroldi, Meshell Morrison et al.|The Lancet Infectious Diseases|2024Cited by 8
Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Humans is Diminished by Priming with a Yellow Fever or Japanese Encephalitis Virus Vaccine: Elucidating Immunologic Interference between Flavivirus VaccinesKayvon Modjarrad, Nelson L. Michael, Rafael De La Barrera et al.|The Journal of Immunology|2020Cited by 1